手机买球 announces new collaboration and $10 million investment pledge from 第一三共制药 Inc.

的 funds will be invested by the Hatch VC fund into early stage and startup companies that are 手机买球 members.

 美国多伊尔斯敦,  3月31日, 2021 – 的 nonprofit Pennsylvania Biotechnology Center (手机买球), one of the nation’s most successful life sciences incubators, today announced a new collaboration that includes a pledge by 第一三共制药 to become an investor in the fund managed by Hatch Biofund Management LLC.

An investment of $10 million has been committed by 第一三共制药 to Hatch Biofund 1, which was created by the Baruch S. Blumberg Institute as a companion to their Incubator and BioAccelerator. 的 手机买球 is managed by the Blumberg Institute. Hatch Biofund is currently in a fundraising mode with plans to raise $50 million with a first close within months.

路易斯·P. 卡萨岛, the 手机买球’s executive vice president and chief operating officer, 说, “Having 第一三共制药 join our innovation ecosystem is a big win for the 手机买球 and our 70-plus member companies, and it’s a win for Bucks County, the Philadelphia region and the State of Pennsylvania as well.”

第一三共制药’s interests in oncology and cell and gene therapy align well with the current 手机买球 incubator.

“This collaboration provides 第一三共制药 with access to the new therapeutics under development in the incubators as well as a front row seat at the birth of the new cell and gene therapy industry 在这里 in our region,“弗拉德Walko, 舱口的首席执行官, 说. “的 lead investment in Hatch reflects 第一三共制药’s confidence in the 手机买球 model and in the Philadelphia region as a major biotech hub.”

第一三共制药, one of the largest pharmaceutical companies in Japan with sales of more than  $9 billion, 有它你.S. headquarters in Basking Ridge, N.J. "At 第一三共制药, we are committed to exploring and investing in a variety of avenues to improve health and extend lives,” 说 Stu Mackey, Global Head of Business Development, 第一三共制药. “We are proud to partner with the Pennsylvania Biotechnology Center to support the advancement of companies that share our goals for better global human health.” 

手机正规买球 the Pennsylvania Biotechnology Center (手机买球): 的 手机买球 is a nonprofit life sciences incubator-accelerator, offering state-of-the-art laboratory and office space to early stage biotech companies, as well as the Hepatitis B Foundation and Blumberg Institute. Managed by the Institute and led by a board appointed by the Foundation, 手机买球 has nearly 80 member companies, mostly small to mid-size science, research and pharmaceutical companies. More than 40 of those companies have operations on site. 的 center uses a highly successful services-based approach to nurture and guide its member companies to success, advancing biotechnology, maximizing synergies among nonprofit scientists and their commercial colleagues, and launching new ideas and discoveries that will make a difference. 手机买球 is just outside of 美国多伊尔斯敦 in Bucks County, in the heart of the Philadelphia-New Jersey pharma belt. 的 手机买球网站 provides details about 手机买球 membership options and upcoming events. To make a donation to the 手机买球, click 在这里.

手机正规买球 the Hatch Biofund: This new venture capital fund is a companion to the incubators and bioaccelerators owned or managed by the 手机买球. Hatch Biofund Management is raising $50 million to invest in the most promising early stage and seed-stage companies that are members of the 手机买球. A prestigious Scientific Advisory Board and experienced 投资ment Committee review and approve all investments. Significant risk mitigation within the 手机买球 Ecosystem has been studied by independent fund auditors and is believed to be reflected in outsized investor returns, shortened exit times and extremely low failure rate.  Hatch Biofund Management offices are located at the 手机买球. For further information, please contact Vladimir Walko, CEO and Fund Manager.